- Home
- ERAS vs ITOS Comparison
ERAS vs ITOS Comparison
Compare ERAS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- ITOS
- Stock Information
- Founded
- ERAS 2018
- ITOS 2011
- Country
- ERAS United States
- ITOS United States
- Employees
- ERAS N/A
- ITOS N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ERAS Health Care
- ITOS Health Care
- Exchange
- ERAS Nasdaq
- ITOS Nasdaq
- Market Cap
- ERAS 484.4M
- ITOS 450.9M
- IPO Year
- ERAS 2021
- ITOS 2020
- Fundamental
- Price
- ERAS $1.58
- ITOS $10.13
- Analyst Decision
- ERAS Strong Buy
- ITOS Hold
- Analyst Count
- ERAS 6
- ITOS 6
- Target Price
- ERAS $4.50
- ITOS $10.40
- AVG Volume (30 Days)
- ERAS 714.7K
- ITOS 1.1M
- Earning Date
- ERAS 08-12-2025
- ITOS 08-06-2025
- Dividend Yield
- ERAS N/A
- ITOS N/A
- EPS Growth
- ERAS N/A
- ITOS N/A
- EPS
- ERAS N/A
- ITOS N/A
- Revenue
- ERAS N/A
- ITOS N/A
- Revenue This Year
- ERAS N/A
- ITOS N/A
- Revenue Next Year
- ERAS N/A
- ITOS N/A
- P/E Ratio
- ERAS N/A
- ITOS N/A
- Revenue Growth
- ERAS N/A
- ITOS 177.89
- 52 Week Low
- ERAS $1.01
- ITOS $4.80
- 52 Week High
- ERAS $3.31
- ITOS $18.01
- Technical
- Relative Strength Index (RSI)
- ERAS 53.64
- ITOS 52.11
- Support Level
- ERAS $1.44
- ITOS $10.10
- Resistance Level
- ERAS $1.64
- ITOS $10.22
- Average True Range (ATR)
- ERAS 0.10
- ITOS 0.05
- MACD
- ERAS 0.01
- ITOS -0.01
- Stochastic Oscillator
- ERAS 61.54
- ITOS 28.00
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.